Use of GLP-1 RAs in cardiovascular disease prevention: a practical guide
Because of this complexity, conventional analytical techniques are often not sensitive enough to fully characterize them
Platforms like Ro are also playing a role in helping patients navigate different treatment options and insurance coverage, making it easier to find more affordable paths to these medications. BENEOs Colindres explains that the costs associated with GLP-1s not only limits initial adoption, but continued use
Most providers do not recommend stopping the medication entirely for mild-to-moderate diarrhea, as this side effect typically resolves during continued treatment
Hence, while the integrity of the randomization must be respected in any analysis of an RCT, the question on what to do about post-randomization effect modifiers remains and must be discussed
doi: 10.1186/1471-2458-13-1068